Junshi Biosciences Announces Acceptance of Supplemental Application for Additional Indications of Adalimumab Injection

By Dr. Matthew Watson

-- Additional indications: treatment for Crohn’s disease, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis and pediatric Crohn’s disease

View post:
Junshi Biosciences Announces Acceptance of Supplemental Application for Additional Indications of Adalimumab Injection

Telesis Bio Announces Reverse Stock Split - May 7th, 2024
Shockwave Medical Reports First Quarter 2024 Financial Results - May 7th, 2024
Aileron Therapeutics to Present at Two Upcoming Investor Conferences - May 7th, 2024
ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates - May 7th, 2024
Sana Biotechnology to Present at May and June 2024 Investor Conferences - May 7th, 2024
Day One Reports First Quarter 2024 Financial Results and Corporate Progress - May 7th, 2024
Immuneering Recognizes Melanoma Awareness Month - May 7th, 2024
T2 Biosystems Announces the Conversion of an Additional $15 Million of CRG Term Loan into Equity - May 7th, 2024
Helio Genomics to Showcase Results from CLiMB Pivotal Trial in an Oral Presentation at the EASL Congress 2024 - May 7th, 2024
T2 Biosystems Announces Commercial Expansion Through Middle East Distributor - May 7th, 2024
Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024 - May 7th, 2024
BioVersys Announces Expansion of Strategic Collaboration With GSK and Extension of Its Series C Round by CHF 12.3 Million - May 7th, 2024
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 7th, 2024
T2 Biosystems Announces First Quarter 2024 Financial Results - May 7th, 2024
argenx to Present at BofA Securities 2024 Health Care Conference - May 7th, 2024
Ultimovacs ASA Reports First Quarter 2024 Financial Results and Provides General Business Update - May 7th, 2024
Sandoz reports first quarter 2024 sales - May 7th, 2024
Memo Therapeutics increases Series C financing to CHF 45 million - May 7th, 2024
Orion Corporation: Change in Orion Group Executive Management Board as of 31 May 2025 - May 7th, 2024
Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates - May 7th, 2024
Medigene AG reports Financial Results and Business Update for Q1 2024 - April 28th, 2024
Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting - April 28th, 2024
Novo Nordisk A/S – Total number of voting rights and share capital in Novo Nordisk A/S as of 26 April 2024 - April 28th, 2024
Composition of the Nomination Committee of Orion Corporation - April 28th, 2024
Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA) - April 28th, 2024
Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024 - April 28th, 2024
Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024 - April 28th, 2024
Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal... - April 28th, 2024
Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP) - April 28th, 2024
HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda - April 28th, 2024
Medicenna Therapeutics Announces CA$20 Million Investment from RA Capital Management - April 28th, 2024
Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024 - April 28th, 2024
Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments - April 28th, 2024
UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting - April 28th, 2024
CARBIOS celebrates the groundbreaking of its PET biorecycling plant, a world first, with its partners - April 28th, 2024
BioSenic publishes on its website the restructuring plan submitted to the Enterprise Court of Nivelles - April 28th, 2024
Sino Biological Finalizes the Acquisition of SignalChem Biotech, Strengthening Global Presence and Expanding Product Portfolio - April 28th, 2024
Rakovina Therapeutics Inc. Announces 2023 Financial Results and Provides Corporate Update - April 28th, 2024
Cronos Group Inc. to Hold Virtual 2024 Annual Meeting of Shareholders - April 28th, 2024
Financière de Tubize - Dividend approval - April 28th, 2024
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant... - April 19th, 2024
Telesis Bio Inc. announces strategic focus on game-changing Gibson SOLA enzymatic DNA synthesis (EDS) platform and BioXp mRNA solutions and announces... - April 19th, 2024
Sanara MedTech Inc. Announces $55 Million Debt Facility - April 19th, 2024
Pharming Group announces the placement of €100 million convertible bonds due 2029 - April 19th, 2024
Digital Utilities Ventures Completes Strategic Merger - Paving the Way for Future Growth and Innovation - April 19th, 2024
Referat Fra Ordinær Generalforsamling Den 18. April 2024 Kl. 15:00 - April 19th, 2024
Nexcella, an Immix Biopharma Subsidiary, on Track to Dose NXC-201 Patients in United States - April 19th, 2024
Immix Biopharma on Track to Dose NXC-201 Patients in United States - April 19th, 2024
Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C. - April 19th, 2024
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine - April 19th, 2024
ANI Pharmaceuticals to Discuss First Quarter 2024 Financial Results on May 10, 2024, at 8:30 a.m. ET - April 19th, 2024
NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer’s &... - April 19th, 2024
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings - April 19th, 2024
Celularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted... - April 19th, 2024
Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections - April 19th, 2024
Codexis to Report First Quarter 2024 Financial Results on May 2 - April 19th, 2024
Addex to Present at the Swiss Biotech Day 2024 - April 19th, 2024
Histogen Files for Voluntary Chapter 11 Protection to Facilitate Wind-Down, Maximize Share Offering - April 19th, 2024
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs - April 19th, 2024
FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer - April 19th, 2024
Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B... - April 10th, 2024
Ultimovacs – Invitation to Business Update on April 17, 2024 - April 10th, 2024
Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective... - April 10th, 2024
Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis - April 10th, 2024
Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024 - April 10th, 2024
Rakovina Therapeutics Presented at American Association of Cancer Research Annual Meeting at the San Diego Convention Center Today - April 10th, 2024
ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024 - April 10th, 2024
Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors - April 10th, 2024
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious... - April 10th, 2024
Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results - April 10th, 2024
Certara to Report First Quarter 2024 Financial Results on May 7th, 2024 and Participate in the BofA Securities Healthcare Conference - April 10th, 2024
Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2... - April 10th, 2024
Frontier Medicines Presents New Data for First-In-Class Dual ON+OFF KRAS G12C Inhibitor FMC-376 at the AACR Annual Meeting - April 10th, 2024
IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024 - April 10th, 2024
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300... - April 10th, 2024
Auron Unveils Preclinical Data Supporting its Lead Program and Ability of its AURIGIN™ Platform to Generate Targeted Cancer Therapies at AACR Annual... - April 10th, 2024
Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting - April 10th, 2024
Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024 - April 10th, 2024
ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients... - April 10th, 2024
Recce Pharmaceuticals Selected by UK Government Innovation Agency to Participate in AMR Mission 2024 - April 10th, 2024

Global News Feed commento

Comments Off | data

August 18th, 2022

About... Dr. Matthew Watson

This author published 5512 posts in this site.

Comments are closed.

Previous post - Next post

Junshi Biosciences Announces Acceptance of Supplemental Application for Additional Indications of Adalimumab Injection

By Dr. Matthew Watson

About... Dr. Matthew Watson

Share

Comments are closed.

Categories

Archives

Recommended Sites